← Leaderboards
Benjamin W Van Tassell
Virginia Commonwealth University
$3,632,226
Attributed
$7,264,451
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,264,451 · 6
By mechanism
R01$2,490,717 · 1
R33$2,240,366 · 1
R34$2,000,694 · 3
R61$532,674 · 1
Top collaborators
- Antonio Abbate16 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Ross B Mikkelsen$7,091,746
- Jordana Kron$245,581
- William Gregory Hundley$19,718,962
- Vasily Yakovlev$733,184
Others in their field
Top investigators on “Morbidity - Disease Rate”
- Marco Pahor · Wake Forest University Health Sciences$29,421,775
- A Benedict Cosimi · Massachusetts General Hospital$17,236,164
- Judith S. Currier · University Of California Los Angeles$11,229,603
- Andrea Jenay Ruff · Johns Hopkins University$10,896,035
- Lucile L Adams-Campbell · Howard University$10,384,616
- Michael K Ong · University Of California Los Angeles$9,898,332
Research focus
Morbidity - Disease RateHospitalizationQuality Of LifeDouble-Blind MethodAnakinraHeart FailureInflammatoryPlacebosAcuteInterleukin-1CardiacRandomizedCytokineIncidenceInflammationOxygen ConsumptionHospitalsImpairmentCardiopulmonaryClinical TrialsPhase Iii Clinical TrialsBiological MarkersAnti-Inflammatory AgentsFunctional Disorder
Grant awards (16)
Prevention of heart failure with IL-1 blockade: a mechanistic study$608,382
R01 · FY2025 · AG · contact PI
Prevention of heart failure with IL-1 blockade: a mechanistic study$620,799
R01 · FY2024 · AG · contact PI
Prevention of heart failure with IL-1 blockade: a mechanistic study$620,799
R01 · FY2023 · AG · contact PI
Prevention of heart failure with IL-1 blockade: a mechanistic study$640,737
R01 · FY2022 · AG · contact PI
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure$573,435
R33 · FY2022 · HL · contact PI
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure$572,689
R33 · FY2021 · HL · contact PI
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure$547,121
R33 · FY2020 · HL · contact PI
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure$547,121
R33 · FY2019 · HL · contact PI
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure$532,674
R61 · FY2018 · HL · contact PI
Interleukin-1 blockade in acute myocardial infarction$221,811
R34 · FY2016 · HL
Interleukin-1 blockade in heart failure with preserved ejection fraction$337,978
R34 · FY2015 · HL
Interleukin-1 blockade in acute myocardial infarction$212,907
R34 · FY2015 · HL
Interleukin-1 blockade in heart failure with preserved ejection fraction$343,125
R34 · FY2014 · HL
Interleukin-1 blockade in recently decompensated heart failure$340,316
R34 · FY2014 · HL · contact PI
Interleukin-1 blockade in acute myocardial infarction$214,050
R34 · FY2014 · HL
Interleukin-1 blockade in recently decompensated heart failure$330,507
R34 · FY2013 · HL · contact PI